Mucinous Carcinoma with Neuroendocrine Differentiation of Salivary Gland Origin

Wong, Franklin J.; Zumsteg, Zachary S.; Langevin, Claude-Jean; Ali, Nabilah; Maclary, Shawn; Balzer, Bonnie; Ho, Allen S.

doi:10.1007/s12105-016-0750-5

Cited by 5 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,2,7 EMPSGC as well as a subset of metastatic breast carcinomas, salivary gland carcinomas, and malignant sweat gland tumors can show nuclear ER, PR, and GATA-3 expression. 1,7,11,13,20,21 concordant with prior investigations suggesting that this marker may also be useful in its workup; however, additional cases would need to be assessed in order to compare its performance to SYN and CHR in this related entity. Lastly, our data are in agreement with those of previous investigations suggesting that GATA-3, ER, and PR cannot distinguish EMPSGC and PCMC from metastatic adenocarcinomas of extracutaneous origins.…”

Section: Next Generation Sequencingsupporting

confidence: 79%

“…1,2,7 EMPSGC as well as a subset of metastatic breast carcinomas, salivary gland carcinomas, and malignant sweat gland tumors can show nuclear ER, PR, and GATA-3 expression. 1,7,11,13,20,21 Therefore, pathologists should not rely on them to determine the site of origin for a mucinous cutaneous adenocarcinoma. ER, PR, and GATA-3 also labeled our case of PCMC and the PCMC present in association with a case of EMPSGC.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparative performance of insulinoma‐associated protein 1 (INSM1) and routine immunohistochemical markers of neuroendocrine differentiation in the diagnosis of endocrine mucin‐producing sweat gland carcinoma

et al. 2020

View full text Add to dashboard Cite

Endocrine mucin-producing sweat gland carcinoma (EMPSGC) is a rare cutaneous adnexal malignancy with predilection for the eyelids of older adults. It must be distinguished from metastatic adenocarcinomas of extracutaneous origin and from benign adnexal proliferations on partial samples when a solid growth component and mucin production are not evident. Thus, demonstration of neuroendocrine differentiation can help to ensure a correct diagnosis. Insulinoma-associated protein 1 (INSM1) is a novel neuroendocrine marker that has recently shown greater sensitivity than synaptophysin (SYN) and chromogranin (CHR) in the diagnosis of various neuroendocrine neoplasms. We compared the performance of these three markers across 10 examples of EMPSGC. All EMPSGCs expressed INSM1. Eight of ten were also immunoreactive for SYN; however, INSM1 staining was generally more intense and stained a greater proportion of the tumor cells. CHR staining was weak and focal in most cases. INSM1 staining was present in hidrocystoma-like components of cystic EMPSGC. These findings suggest that INSM1 may be more sensitive than SYN and CHR and thus valuable for establishing a diagnosis of EMPSGC.

show abstract

Section: Next Generation Sequencingsupporting

confidence: 79%

“…1,2,7 EMPSGC as well as a subset of metastatic breast carcinomas, salivary gland carcinomas, and malignant sweat gland tumors can show nuclear ER, PR, and GATA-3 expression. 1,7,11,13,20,21 Therefore, pathologists should not rely on them to determine the site of origin for a mucinous cutaneous adenocarcinoma. ER, PR, and GATA-3 also labeled our case of PCMC and the PCMC present in association with a case of EMPSGC.…”

Section: Discussionmentioning

confidence: 99%

Comparative performance of insulinoma‐associated protein 1 (INSM1) and routine immunohistochemical markers of neuroendocrine differentiation in the diagnosis of endocrine mucin‐producing sweat gland carcinoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Because of positivity for GATA 3 ( an immunomarker found for example in breast and salivary glands but also in skin tumors [5,6] and expression of mammaglobin, an immunohistochemical marker found in breast cancer [7], mammography was done also and ultrasonography was performed to rule out a salivary gland origin because of its anatomic proximity. Moreover, colonoscopy was performed because of positive staining for mucin (MUC) 2 and 6, as well as cytokeratin 7 (CK7).…”

Section: Case Reportmentioning

confidence: 99%

Limitations of Immunohistochemistry in Diagnosis of a Primary Mucinous Carcinoma of the Skin and Its Metastasis

Mann

Schad

Mann³

et al. 2020

Asp Biomed Clin Case Rep

View full text Add to dashboard Cite

We describe the case of a 67-year-old female patient who presented with an unclear swelling on the right supraclavicular neck, two years after resection of a mucinous carcinoma on the right mastoid. Two pathological reports from separate universities diagnosed the primary mastoid skin lesion as a metastatic adenocarcinoma. Strikingly, GATA binding protein 3 (GATA3) and mammaglobin, both immunomarkers found in breast cancer, were positive. An urgent search for the primary tumor most likely in the breast was commenced. However, as no other primary tumor could be detected at that time, a Primary Mucinous Carcinoma of the Skin (PMCS) was also debated. Two years later neck node enlargement was suspicious for lymph node metastasis during ultrasound examination and conservative neck dissection was performed. Immunohistochemistry revealed again GATA 3, Mammaglobin, estrogen, and progesterone receptor positive tissue. Using a variety of other markers, we were unable to detect neither significant morphological nor immunohistochemical characteristics that distinguished the lesion from a mucinous carcinoma of mammary origin. Following a detailed review of the clinical context, we concluded the lesion to be consistent with a late metastasis of a PMCS. This report demonstrates the limitations of currently used histopathological and immunohistochemical differentiation in metastatic mucinous carcinoma.

show abstract

Surgical Perspectives in Head and Neck Cancer

Maghami

2018

Cancer Treatment and Research

View full text Add to dashboard Cite

Head and neck cancer treatment is a complex multidisciplinary undertaking. Cancer cure and survival is a primary goal, yet safe-guarding appearance and function to preserve the quality of life are similarly critical. The head and neck surgeon remains central to multidisciplinary cancer care, with deep knowledge of operative technique and an even deeper understanding of cancer biology. The surgeon models practice based on the highest levels of scientific evidence, but also takes into consideration the approaches that may best suit an individual patient. The surgeon's role moreover spans the life history of a head and neck cancer patient, from diagnosis to surveillance. The intimacy of this role makes the surgeon a trusted and frequent frame of reference for the patient. In this chapter, we provide an overview of the surgeon's role in head and neck cancer management. We discuss surgical perspectives within the multidisciplinary care team and selectively highlight some of the more provocative clinical scenarios in the field.

show abstract

Mucinous Carcinoma with Neuroendocrine Differentiation of Salivary Gland Origin

Cited by 5 publications

References 15 publications

Comparative performance of insulinoma‐associated protein 1 (INSM1) and routine immunohistochemical markers of neuroendocrine differentiation in the diagnosis of endocrine mucin‐producing sweat gland carcinoma

Comparative performance of insulinoma‐associated protein 1 (INSM1) and routine immunohistochemical markers of neuroendocrine differentiation in the diagnosis of endocrine mucin‐producing sweat gland carcinoma

Limitations of Immunohistochemistry in Diagnosis of a Primary Mucinous Carcinoma of the Skin and Its Metastasis

Surgical Perspectives in Head and Neck Cancer

Contact Info

Product

Resources

About